Home > NewsRelease > Atrantil IBS-C Clinical Trial Results Published
Text
Atrantil IBS-C Clinical Trial Results Published
From:
Kenneth Brown, M.D. -- Board-Certified Gastroenterologist Kenneth Brown, M.D. -- Board-Certified Gastroenterologist
For Immediate Release:
Dateline: Dallas, TX
Saturday, October 10, 2015

 

As most of you know, we set out eight years ago to find a treatment for my patients who came to me complaining that they looked nine months pregnant from bloating and who had horrible IBS-C symptoms. At the time, there was really no effective treatment out there and we saw the need. We decided to make something all natural that would not only take away these IBS symptoms, but also be really good for you; enhanced with flavonoids, anti-oxidants, and other great properties, such as anti-inflammatory agents. We wanted to make something here, in the US, with only the purest ingredients that we would be proud to stand behind. That was how Atrantil was born.

Holding to this standard, we decided that even though it was not required, we wanted to hold it to FDA standards and run clinical trials on our new product. Many of you have asked about these trials and finally we can share our excitement. For all of you wanting to know about our clinical trials, we have great news! Our pilot study on Atrantil was such a success, that we were just published in The Journal of Gastroenterology and Hepatology Research.

We conducted a Two Week, Double Blind, Randomized, Placebo-Controlled Study on Atrantil to determine the safety and efficacy in patients with IBS-C. The inclusion criteria included patients diagnosed with IBS-C at least 6 months prior to randomization. The patients were randomized into the Atrantil treatment arm or the placebo arm for a treatment period of two weeks. We measured overall Quality Of Life (QOL) as well as Constipation and Bloating Scores before and after treatment. The patients were able to take Atrantil on an as-needed basis up to three times per day.

We are happy to report that we saw outstanding results! When the statistical analysis was done, the p-value was less than 0.001 for all scores. What that means is that the results we saw were statistically significant. An astonishing 90% of the patients on Atrantil saw improvement. The overall QOL was 70% greater for those on Atrantil than those on placebo. The bloating scores improved by 58% and constipation improved by 31%. This was a tremendous showing, considering pharmaceuticals are only 8-10% better than placebo when approved by the FDA.

During the study, we also had no adverse events reported by any of the patients. This is because the ingredients are all natural and actually great for you!

We are really excited to share this data with you and encourage you to read the actual publication in The Journal of Gastroenterology and Hepatology Research . We hope you share our excitement and help spread the word about the benefits of Atrantil. Along with your help, we hope to improve the world’s digestive health one tummy at a time!

Written By: Kenneth Brown, M.D.

News Media Interview Contact
Name: Kenneth Brown, M.D.
Dateline: Plano, TX United States
Direct Phone: 972-867-0019
Jump To Kenneth Brown, M.D. -- Board-Certified Gastroenterologist Jump To Kenneth Brown, M.D. -- Board-Certified Gastroenterologist
Contact Click to Contact